<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01211431</url>
  </required_header>
  <id_info>
    <org_study_id>AOI/2008/GA-01</org_study_id>
    <secondary_id>2008-004643-11</secondary_id>
    <nct_id>NCT01211431</nct_id>
  </id_info>
  <brief_title>Post-cesarean Pain Control Via Continuous Infusion of Ropivacain et Diclogenac Into the Wound Versus Intathecal Morphine</brief_title>
  <official_title>Post-cesarean Pain Control Via Continuous Infusion of Ropivacain et Diclogenac Into the Wound Versus Intathecal Morphine: Comparison of the Quality of Analgesia, Side Effects, and the Incidence of Residual Scar Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal is to compare the quality of post-cesarean analgesia, the side effects and the
      incidence of residual scar pain obtained with intrathecal morphine (reference treatment) or
      with a continuous intra-wound solution including both ropivacain and diclofenac (experimental
      treatment).
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No inclusions.
  </why_stopped>
  <start_date>September 2010</start_date>
  <completion_date type="Anticipated">October 2012</completion_date>
  <primary_completion_date type="Anticipated">October 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary VAS score</measure>
    <time_frame>36 hours post delivery</time_frame>
    <description>The patient is asked to evaluate cesarean-section related pain using a visual analog scale (VAS) score for pain on a scale of 1-10 in a sitting position.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Cesarean Section</condition>
  <arm_group>
    <arm_group_label>Reference</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intrathécale morphine is used for post-cesarean pain control</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A solution including both ropivacain and diclofenac continuously delivered to the wound is used for post-cesarean pain control</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reference</intervention_name>
    <description>Intrathécale morphine is used for post-cesarean pain control</description>
    <arm_group_label>Reference</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Experimental</intervention_name>
    <description>A solution including both ropivacain and diclofenac continuously delivered to the wound is used for post-cesarean pain control</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  single, normally progressing pregancy

          -  term &gt; 36 weeks amenorrhea

          -  BMI between 20 and 25 kg/m^2 before pregnancy

          -  height between 55 and 90 kg

          -  cesarean section by Joel-Cohen or Pfannenstiel techniques

          -  patient has signed consent

          -  patient has social security coverage

        Exclusion Criteria:

          -  Multiple pregnancy

          -  pathological pregnancy: hypertension (&gt;140/90 mmHg found during the pregnancy),
             pre-eclampsia, gestational diabetes

          -  term &lt; 36 weeks amenorrhea

          -  non-pregnancy related maternal pathology (insufficiency)

          -  obesity (BMI &gt; 25 kg/m^2 before pregnancy)

          -  height &lt; 155 cm or &gt; 180 cm

          -  weight &lt; 55 kg or &gt; 90 kg

          -  patient refuses to sign consent

          -  surgical technique other than Joel-Cohen or Pfannenstiel

          -  hepatic insufficiency (prothrombin &lt; 60%)

          -  contra-indications for rachianesthesia: infection, hemostasis problems (platelets &lt;
             80.109/L, prothrombin &lt; 60%, TCA &gt; 40s)

          -  allergy to local anesthestics

          -  patient is participating in another study, or has participated in another study within
             the last 6 months

          -  patient is under any type of guardianship
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antoinie Guy Aya, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Nîmes</affiliation>
  </overall_official>
  <removed_countries>
    <country>France</country>
  </removed_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 28, 2010</study_first_submitted>
  <study_first_submitted_qc>September 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2010</study_first_posted>
  <last_update_submitted>March 24, 2015</last_update_submitted>
  <last_update_submitted_qc>March 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cesarean section</keyword>
  <keyword>pain</keyword>
  <keyword>ropivacain</keyword>
  <keyword>diclofena</keyword>
  <keyword>morphine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

